Arylamine N-acetyltransferases and Drug Response
- 1 May 2002
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 3 (3) , 349-366
- https://doi.org/10.1517/14622416.3.3.349
Abstract
Arylamine N-acetyltransferases (NATs) play an important role in the interaction of competing metabolic pathways determining the fate of and response to xenobiotics as therapeutic drugs, occupational chemicals and carcinogenic substances. Individual susceptibility for drug response and possible adverse drug reactions are modulated by the genetic predisposition (manifested for example, by polymorphisms) and the phenotype of these enzymes. For all drugs metabolized by NATs, the impact of different in vivo enzyme activities is reviewed with regard to therapeutic use, prevention of side effects and possible indications for risk assessment by phenotyping and/or genotyping. As genes of NATs are susceptibility genes for multifactorial adverse effects and xenobiotic-related diseases, risk prediction can only be made possible by taking the complexity of events into consideration.Keywords
This publication has 199 references indexed in Scilit:
- Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2Canadian Journal of Physiology and Pharmacology, 1998
- The role of acetylation in the mutagenicity of the antitumor agent, batracylinCarcinogenesis: Integrative Cancer Research, 1996
- Inhibition of N‐Acetylation of Procainamide and Renal Clearance of N‐Acetylprocainamide by Para‐Aminobenzoic Acid in HumansThe Journal of Clinical Pharmacology, 1995
- Pharmacological Rationale for the Clinical Use of CaffeineDrugs, 1995
- Metabolic polymorphisms affecting activation of toxic and mutagenic arylaminesTrends in Pharmacological Sciences, 1992
- The Effect of Age and Acetylator Phenotype on the Pharmacokinetics of Sulfasalazine in Patients with Rheumatoid ArthritisClinical Pharmacokinetics, 1992
- Acecainide (N-Acetylprocainamide)Drugs, 1990
- Procainamide: Autoimmune Phenomena and Acetylator PhenotypeNew England Journal of Medicine, 1985
- Population Pharmacokinetics of Procainamide from Routine Clinical DataClinical Pharmacokinetics, 1984
- Formal Genetics of Isoniazid Metabolism in ManClinical Pharmacokinetics, 1983